Meaningful clinical evidence-generation and extensive real-world use
Stent performance that endures
RESOLUTE POOLED9 ANALYSIS OF STENT THROMBOSIS (ARC DEF/PROB) THROUGH FIVE YEARS
RESOLUTE POOLED9 ANALYSIS OUTCOMES THROUGH FIVE YEARS
Resolute™ ZES (N = 7618)
Resolute Onyx DES — excellent safety in real-world study
One-Year Clinical Outcomes of Patients Treated with Resolute Onyx DES vs. Resolute Integrity™ DES : an Interim Study of HOST-ONYX and HOST-RESOLINTE Registries11
Based on bench test data. May not be indicative of clinical performance.
2
Compared with Resolute Integrity DES in benchtop testing. Data on file at Medtronic. May not be indicative of clinical performance.
3
Bench test data on file at Medtronic. May not be indicative of clinical performance. Testing performed on smallest diameters available for Abbott Xience Alpine™*, Biotronik Orsiro™*, Boston Scientific Promus Premier™*, Boston Scientific Synergy™*, Medtronic Resolute Integrity™, and Medtronic Resolute Onyx™ coronary stents. Biotronik Orsiro™* DES is not approved in the USA as of 21-FEB-2018.
4
The Resolute Onyx stents should not be expanded to a diameter beyond the maximum labeled diameter listed on the label per the IFU. Do not dilate the 2.0-mm stents to greater than 3.25 mm. Postdilation required for overexpansion.
5
Price et al. JACC Cardiovascular Interventions. 2017;10(14):1381–1388.
Study only powered for TLF clinical endpoint. Rates are taken from KM estimates
6
The Resolute Onyx stents should not be expanded to a diameter beyond the maximum labeled diameter listed on the label per the IFU. Do not dilate the 4.5- and 5.0-mm stents to greater than 5.75 mm.
7
Based on bench test data. May not be indicative of clinical performance.
8
Based on net sales data of Resolute DES, Resolute Integrity DES, and Resolute Onyx DES through Q3FY2017.
9
Yeh et al.5-year safety and efficacy of Resolute zotarolimus-eluting stent. JACC Cardiovascular Interventions. 2017;10:247–254.